An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial.
Riche
Daniel M
DM
Department of Pharmacy Practice, University of Mississippi, Jackson, MS, USA. driche@sop.umsmed.edu
Minor
Deborah S
DS
Holdiness
Amber S
AS
East
Honey E
HE
D000577:Amides / Q000008:administration & dosage*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000150:complications / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005650:Fumarates / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D011507:Proteinuria / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005650:Fumarates; C446481:aliskiren